Enhancing Patient Outcomes with BCMA-Targeting Bispecific Antibodies: Infection Risks

Overview

Bispecific antibodies targeting BCMA demonstrate significant efficacy in multiple myeloma but are associated with a high incidence of infections, including severe and opportunistic infections. Strategies such as intravenous immunoglobulin prophylaxis and dosing interval optimization have shown promise in mitigating these infection risks.

Background

Multiple myeloma patients are inherently susceptible to infections due to immune dysfunction. Anti-BCMA therapies, including CAR T-cells and bispecific antibodies, have transformed treatment but further increase infection risk due to hypogammaglobulinemia and immune cell depletion. BCMA is expressed on malignant and normal plasma cells as well as B cell progenitors, contributing to immunosuppression. Understanding and managing infection risks is critical to optimizing patient outcomes with these novel therapies.

Data Highlights

Key Findings

• Infections are common and often severe in patients treated with anti-BCMA bispecific antibodies, with grade ≥3 infections occurring in 40% of patients and infection-related deaths at 7%.
• Hypogammaglobulinemia (IgG <400 mg/dL) is frequent with anti-BCMA bispecific antibodies, contributing to increased infection risk.
• Infection risk timing differs: CAR T-cell patients have higher severe infection risk in the first 100 days, whereas bispecific antibody patients have ongoing infection risk beyond six months.
• Intravenous immunoglobulin (IVIG) prophylaxis significantly reduces serious infections in patients with hypogammaglobulinemia receiving bispecific antibodies.
• Extending dosing intervals of bispecific antibodies (e.g., from weekly to every two weeks) reduces infection rates without compromising efficacy.
• Anti-BCMA therapies targeting BCMA affect normal B cell populations, unlike GPRC5D-targeting agents, which may explain differences in infection risk profiles.

Clinical Implications

Clinicians should monitor immunoglobulin levels closely in patients receiving anti-BCMA bispecific antibodies and consider early initiation of IVIG prophylaxis when IgG falls below 400 mg/dL. Adjusting dosing intervals to less frequent schedules can reduce infection risk while maintaining treatment efficacy. Awareness of the prolonged infection risk with bispecific antibodies compared to CAR T-cell therapy is essential for patient management and counseling.

Conclusion

Anti-BCMA bispecific antibodies offer transformative efficacy in multiple myeloma but carry a substantial infection risk driven by hypogammaglobulinemia and immune cell targeting. Prophylactic IVIG and dosing interval optimization are effective strategies to mitigate these risks and improve patient outcomes.

References

1. Nath et al. -- Infection Risks with Anti-BCMA Therapies in Multiple Myeloma
2. MajesTEC-1 and MagnetisMM-3 Trials -- Teclistamab and Elranatamab Infection Data
3. CARTITUDE-1 Trial -- Ciltacabtagene Autoleucel Infection Outcomes
4. Population Study of Infection Risk in Multiple Myeloma
5. Amsterdam University Medical Center -- IVIG Prophylaxis Study
6. Mount Sinai Study -- IVIG and Infection Reduction
7. FDA Approval Announcement -- Teclistamab Dosing Interval Update